Bethesda Classification and Risk Stratification in Differentiated Thyroid Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
This observational study aims to evaluate the relationship between preoperative Bethesda classification of fine-needle aspiration cytology and postoperative American Thyroid Association (ATA) risk stratification in patients with differentiated thyroid carcinoma.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Available preoperative fine-needle aspiration cytology (FNAC)
Postoperative histopathologically confirmed differentiated thyroid carcinoma
Disqualifiers
Poorly differentiated thyroid carcinoma
Anaplastic thyroid carcinoma
Medullary thyroid carcinoma
Non-diagnostic FNAC (Bethesda category I)
Trial population
Adult patients with histopathologically confirmed differentiated thyroid carcinoma who underwent preoperative fine-needle aspiration cytology and are followed at the Nuclear Medicine Unit, Assiut University Hospitals.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 1 trial groupGroup A: Patients with Differentiated Thyroid Carcinoma
Trial outcomes
Primary outcomes
1
Proportion of patients with high ATA risk stratification
Proportion of patients classified as high risk according to the American Thyroid Association (ATA) risk stratification system.
Time frame
At 1 monthSecondary outcomes
1
Proportion of patients with papillary thyroid carcinoma subtype
Proportion of patients with papillary thyroid carcinoma histopathological subtype.
Time frame
Baseline2
Proportion of patients receiving radioactive iodine therapy
Proportion of patients who received radioactive iodine (RAI) therapy.
Time frame
At 6 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: